Skip to content
etf.net

GNOM

GradeDNASDAQ Global Market

Global X - Genomics & Biotechnology ETF

Themes · Global X · Inception 2019-04-05 · SEC filings

$67.77−1.51 (−2.18%)

As of Sep 23, 2026, 2:20 PM EDT

Intraday session: down, 59 prints from 69.28 to 67.77. Range 67.77 to 69.50. Use the arrow keys to read each point.$68.00$68.50$69.00$69.5010 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$104M
1Y return
+84.4%
Yield · Last 12 months
0.94%
Holdings
50
Volume · 30D
0M sh
NAV per share
$69.06
52W range
low $37.25high $69.59

The ETF.net GNOM Grade

D

38/ 100

Rank 13 of 17 in Biotech & Genomics⁠

Confidence Medium

Six-pillar profile for GNOM. Scores out of 100: Cost 38, Risk 30, Mission not scored, Tradability 47, Holdings 36, Durability 51. Strongest: Durability (51). Weakest: Risk (30). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 38 of 100 sits in the D band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    DScore 38
    Category rank10/17 · mid-pack

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    DScore 30
    Category rank16/17 · bottom quartile

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    CScore 47
    Category rank9/17 · mid-pack

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    DScore 36
    Category rank15/17 · bottom quartile

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 51
    Category rank10/17 · mid-pack

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

Our read on GNOM

ETF.net Research

DMost biotech ETFs buy the whole drug industry. GNOM buys the genome: gene editing, sequencing, genetic therapies, computational genomics. About 50 global names, one idea, no hedging.

Stated mandate

GNOM seeks to track, before expenses, the performance of the Solactive Genomics Index by investing in companies positioned to benefit from advances in genomic science, including gene editing, sequencing, genetic therapies, computational genomics, and biotechnology.

Why people hold it

  1. 01A genuine pure play. The index targets companies tied to advances in genomic science (gene editing, sequencing, genetic therapies), not the broad pharma complex most biotech funds hold.globalxetfs.com
  2. 02Concentrated on purpose: roughly 50 holdings, global reach. The theme drives the fund instead of being diluted by megacap drugmakers.globalxetfs.com
  3. 03Running since 2019, it is one of the older dedicated genomics baskets, with a multi-year record through a full cycle in the theme.

Worth knowing

  1. 01The narrow screen costs more: 0.50% a year, against 0.44% for IBB, 0.35% for XBI and 0.19% for IBBQ, which own biotech broadly.
  2. 02Thinly traded next to the big biotech funds. Limit orders and mid-session trading matter more here than with a household-name ETF.
  3. 03Small, clinical-stage genomics names swing hard, and with about 50 holdings there is nowhere to hide. Volatility is the price of the pure theme.

GNOM Holdings

As of Sep 21, 2026, 6:06 PM
Asset class
Stocks
Holdings
50
Top-10 weight
53%
Largest holding
MRNA8.0%

Sectors

  • Health Care99.7%
  • Technology0.3%

Geography

  • United States84.08%
  • Netherlands4.96%
  • Hong Kong4.29%
  • Switzerland2.89%
  • Germany2.55%
  • United Kingdom1.23%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001MRNAMODERNA INC7.99%51,887$8M240
002TWSTTWIST BIOSCIENCE CORP7.40%44,291$7M123
003TXG10X GENOMICS INC-CLASS A6.53%85,227$7M136
004GHGUARDANT HEALTH INC5.78%32,209$6M171
005ILMNILLUMINA INC5.30%22,107$5M305
006NTRANATERA INC5.13%13,880$5M223
0071548.HKGENSCRIPT BIOTECH CORP4.29%855,418$4M69
008TECHBIO-TECHNE CORP3.56%49,241$4M184
009BMRNBIOMARIN PHARMACEUTICAL INC3.41%53,273$3M181
010VRTXVERTEX PHARMACEUTICALS INC3.35%6,594$3M417
011QGENQIAGEN N.V.3.13%72,179$3M32
012CRSPCRISPR THERAPEUTICS AG2.89%51,133$3M83
013CAICARIS LIFE SCIENCES INC2.72%90,704$3M83
014ARWRARROWHEAD PHARMACEUTICALS IN2.59%39,020$3M151
015PRAXPRAXIS PRECISION MEDICINES I2.56%8,555$3M103

Showing 1–15 of 50 holdings

GNOM Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

GNOM$18,444
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. GNOM $18,444. SPY $11,723. Use the arrow keys to read each point.$8,818$13,987$19,156Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for GNOM. Periods over one year show the average yearly return.
PeriodGNOM
Year to date+52.6%
1 month+3.8%
3 months+34.0%
1 year+84.4%
3 years+20.0%per year
5 years−5.8%per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for GNOM
YearReturn barGNOM
2026 YTD+52.6%
2025+18.7%
2024−16.0%
2023−8.6%
2022−36.3%
2021−15.9%
2020+51.5%

GNOM in the news

ETF.net Research hasn’t filed on GNOM yet — coverage lands here as it’s written.

GNOM Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
0.94%Last 12 months
Payout per share
$0.65Last 12 months
Last payment
$0.06 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2020–2026

One bar per payment. 5 payments from 2020 to 2026 YTD. Dec 30, 2020 $0.13; Dec 30, 2021 $0.03; Jun 27, 2025 $0.03; Dec 30, 2025 $0.59; Jun 29, 2026 $0.06. Use the arrow keys to read each point.2020202120222023202420252026YTD
Ex-datePay dateAmount per share
Jun 29, 2026Jul 7, 2026$0.06
Dec 30, 2025Jan 7, 2026$0.59
Jun 27, 2025Jul 7, 2025$0.03
Dec 30, 2021Jan 7, 2022$0.03
Dec 30, 2020Jan 8, 2021$0.13

GNOM Risk

How much the fund’s monthly returns vary, scaled to a year.
31.6%
Annualised · 36 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.41
vs 3-month T-bills · to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−70.9%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.60
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

GNOM Cost

Expense ratio0.50%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

8 of the 15 Biotech & Genomics funds charge less.

GNOM costs $50.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.